Tag:

STAT+

Health

FDA Guidance on Antibiotic Use in Animals Faces Criticism | STAT News

by Chief Editor
written by Chief Editor

FDA Tightens the Leash on Livestock Antibiotics: What’s Next for Animal Health and Human Safety?

The Food and Drug Administration (FDA) is taking a firmer stance on antibiotic utilize in food-producing animals, recently issuing guidance for drugmakers to define clear duration limits for medically important antibiotics. This move, announced February 12th by the FDA’s Center for Veterinary Medicine (CVM), aims to curb the rise of antimicrobial resistance (AMR) – a growing threat to both animal and human health.

The Growing Threat of Antimicrobial Resistance

Antimicrobial drugs are vital for treating infections in both people and animals. Though, overuse and inappropriate use of these drugs contribute to AMR, where microorganisms evolve to withstand the effects of medications designed to kill them. As bacteria become resistant, infections become harder, and sometimes impossible, to treat. The FDA recognizes that antibiotic use in animals plays a role in this escalating crisis.

Pro Tip: Medically important antibiotics are those also used to treat human infections. Limiting their use in animals helps preserve their effectiveness for people.

What Does the New Guidance Mean?

Currently, approximately 28% of medically important antibiotics used in cows, pigs, and poultry lack defined durations of use. This allows for potentially prolonged exposure, increasing the risk of resistance development. The FDA’s guidance asks drug companies to revise labeling to include specific criteria for when to start and when to stop administering these antibiotics. This includes suggesting approximate duration ranges for treatment and establishing maximum limits that should not be exceeded. The FDA specifically advises against instructions like “feed until market weight.”

A Five-Year Plan in Motion

This guidance builds on the FDA’s ongoing commitment to antimicrobial stewardship. In 2019, the CVM launched a five-year action plan (2019-2023) to support responsible antibiotic use in veterinary settings. A new plan covering 2024-2028 is now in effect, continuing these efforts. Recent actions include finalizing guidance on defining durations of use (February 12, 2026) and releasing an annual summary report on antimicrobial sales and distribution (December 5, 2025).

Beyond Duration Limits: What Else is on the Horizon?

While duration limits are a crucial step, experts suggest several other trends will shape the future of antibiotic use in livestock:

  • Increased Monitoring: The FDA is actively monitoring antimicrobial sales and distribution data to track usage patterns and identify areas for improvement.
  • Veterinary Oversight: Greater emphasis will likely be placed on veterinary oversight of antibiotic use, ensuring prescriptions are justified and appropriate.
  • Alternative Strategies: Research and development of alternatives to antibiotics – such as vaccines, improved hygiene practices, and novel feed additives – will continue to gain momentum.
  • Focus on Prevention: Proactive measures to prevent disease outbreaks, such as enhanced biosecurity protocols on farms, will become increasingly important.

The Role of Drug Manufacturers

The FDA’s guidance is non-binding, meaning it doesn’t legally compel drug companies to make changes. However, it strongly encourages them to revise product labeling to align with the recommendations. The success of this initiative hinges on the cooperation of the animal drug industry.

Challenges and Concerns

Layoffs at the FDA’s Center for Veterinary Medicine earlier this month have raised concerns about the agency’s capacity to effectively implement and enforce these new guidelines. Interest groups warn that reduced staffing could hamper efforts to curb antimicrobial overuse.

Frequently Asked Questions

What is antimicrobial resistance?
It’s the ability of microorganisms to resist the effects of drugs used to kill them, making infections harder to treat.
Why is antibiotic use in animals a concern?
Antibiotics used in animals can contribute to the development of resistance in bacteria that can transfer to humans.
Is this guidance legally binding?
No, it’s a non-binding recommendation to drug manufacturers.
What are “medically important antibiotics”?
These are antibiotics also used to treat infections in humans.

Want to learn more? Explore the FDA’s resources on antimicrobial resistance: https://www.fda.gov/animal-veterinary/safety-health/antimicrobial-resistance

Share your thoughts on the FDA’s new guidance in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Alzheimer’s Drug Startup Korsana Biosciences Raises $175M

by Chief Editor
written by Chief Editor

Alzheimer’s Drug Development: A Recent Wave of Investment and Innovation

Despite the recent approval of two amyloid-targeting therapies for Alzheimer’s disease, investors are continuing to bet on new approaches to tackling the devastating condition. Korsana Biosciences, a newly launched company, has secured $175 million in funding to advance its own amyloid-clearing treatment, KRSA-028.

The Persistent Pursuit of Amyloid Clearance

For decades, the amyloid hypothesis – the idea that the buildup of amyloid plaques in the brain drives Alzheimer’s disease – has been a central focus of research. KRSA-028, like many previous attempts, aims to break down these amyloid deposits. The continued investment in this approach suggests that, despite setbacks and complexities, the potential remains significant.

Beyond the First Wave: Why More Alzheimer’s Drugs?

With Leqembi and Aduhelm already available, the question arises: is there room for another amyloid-targeting therapy? The answer likely lies in the limitations of existing treatments. These therapies have shown modest clinical benefits and are associated with potential side effects, including ARIA (amyloid-related imaging abnormalities). KRSA-028 may offer a different profile in terms of efficacy, safety, or ease of administration, prompting investors to witness a market opportunity.

The Role of Venture Capital in Alzheimer’s Research

The $175 million investment in Korsana highlights the crucial role of venture capital in driving innovation in the biopharmaceutical sector. Firms like Fairmount, Venrock, Wellington Management, and TCGX are willing to grab risks on early-stage companies with promising technologies, recognizing the potential for substantial returns – and, importantly, the potential to address a major unmet medical need.

The Readout Loud: Insights from Industry Experts

Allison DeAngelis of STAT News, co-host of the biotech podcast “The Readout Loud,” frequently covers these developments. Recent episodes have discussed Pfizer’s Duchenne gene therapy setback, the anticipated approval of new Alzheimer’s treatments, and emerging biotech startups like those founded by Bob Langer.

A Reporter’s Perspective on Biotech and Journalism

DeAngelis’s work, as highlighted in a recent podcast episode, sometimes involves unconventional reporting methods – even purchasing products like vapes and raw milk – to gain firsthand insights into the industries she covers. This dedication to thorough investigation underscores the importance of rigorous journalism in the biotech space.

FAQ: Alzheimer’s Drug Development

  • What is the amyloid hypothesis? The amyloid hypothesis proposes that the buildup of amyloid plaques in the brain is a primary driver of Alzheimer’s disease.
  • What is KRSA-028? KRSA-028 is a new Alzheimer’s treatment being developed by Korsana Biosciences, designed to break down amyloid plaques.
  • Who are the key investors in Korsana Biosciences? Fairmount, Venrock, Wellington Management, and TCGX are among the firms that have invested in Korsana.
  • What is ARIA? ARIA stands for amyloid-related imaging abnormalities, a potential side effect associated with some amyloid-targeting Alzheimer’s therapies.

Pro Tip: Stay informed about the latest developments in Alzheimer’s research by following reputable sources like STAT News and listening to podcasts like “The Readout Loud.”

Explore more articles on biotech and pharmaceutical innovation here.

0 comments
0 FacebookTwitterPinterestEmail
Health

Health Tech: AI, VR, Telehealth & Digital Therapeutics Coverage

by Chief Editor
written by Chief Editor

The Expanding Horizon of Health Tech: Beyond Wearables and AI

The intersection of technology and healthcare is rapidly evolving, moving beyond simple tracking devices and into areas that promise to fundamentally reshape how we approach wellness and disease management. Mario Aguilar, health tech correspondent at STAT, is at the forefront of covering these changes, focusing on the business and policy implications alongside the technological advancements.

The Rise of Digital Therapeutics

While wearable technology like the Apple Watch has garnered attention for its potential in monitoring conditions like Parkinson’s disease, a significant trend is the development of digital therapeutics. These aren’t just apps that track data. they’re evidence-based, clinically evaluated software programs designed to treat medical conditions. Aguilar’s reporting highlights how companies are seeking FDA clearance for these technologies, signaling a shift towards regulated digital health interventions.

AI’s Role: From “Safe” to “Responsible”

Artificial intelligence is no longer a futuristic concept in healthcare; it’s being implemented in diagnostics, drug discovery, and personalized medicine. However, as Aguilar points out, the conversation needs to shift from simply asking if AI is “safe” to determining if it is “responsible.” This encompasses ethical considerations, data privacy, and ensuring equitable access to these technologies.

Telehealth’s Continued Evolution

Telehealth experienced a surge in adoption, and while some of the initial pandemic-driven growth has leveled off, its role in healthcare delivery is solidified. The focus is now on refining telehealth models, integrating them seamlessly with in-person care, and addressing issues like reimbursement and digital literacy.

Virtual and Augmented Reality in Healthcare

Virtual reality (VR) and augmented reality (AR) are finding niche but impactful applications in healthcare. From training surgeons to providing pain management and rehabilitation therapies, these immersive technologies offer unique possibilities. Aguilar’s coverage extends to these emerging areas, exploring their potential to improve patient outcomes and healthcare efficiency.

The Policy and Business Challenges

Technological innovation alone isn’t enough. Aguilar’s work emphasizes the crucial role of policy and business models in realizing the promise of health tech. Questions around data security, reimbursement, and regulatory pathways are central to the successful adoption of these technologies.

Pro Tip: Staying informed about the regulatory landscape is crucial for anyone involved in health tech. The FDA’s approach to digital health is constantly evolving.

The STAT Health Tech Newsletter

For those seeking a deeper dive into these topics, Aguilar co-authors the STAT Health Tech newsletter, a valuable resource for staying up-to-date on the latest developments in the field.

Frequently Asked Questions

  • What types of technology does Mario Aguilar cover? He covers artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.
  • Where can I find Mario Aguilar’s work? His articles are published on STAT News, and he also co-authors the STAT Health Tech newsletter.
  • What is the focus of Aguilar’s reporting? He explores how technology is changing healthcare practice and the business and policy challenges involved.

Seek to learn more about the future of health technology? Explore more articles on STAT News and subscribe to the STAT Health Tech newsletter for regular updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Compass Pathways Psilocybin Shows Promise in Depression Trials | STAT+

by Chief Editor
written by Chief Editor

Psilocybin Therapy: A New Dawn for Treatment-Resistant Depression?

The landscape of mental health treatment is undergoing a significant shift, with psilocybin emerging as a potential breakthrough for individuals battling treatment-resistant depression (TRD). Compass Pathways recently released promising Phase 3 trial results for COMP360, their investigational psilocybin treatment, potentially paving the way for the second psychedelic-assisted therapy to reach the market.

The COMP360 Trials: What the Data Shows

Two Phase 3 trials demonstrated that patients receiving COMP360 experienced greater improvements in depressive symptoms compared to the control groups. The trials measured symptom severity using the Montgomery-Åsberg Depression Rating Scale (MADRS). In one trial, participants receiving a 25mg dose of COMP360 showed a mean reduction in MADRS scores of 3.8 compared to those receiving a 1mg dose (p<0.001). Approximately 39% of participants in this trial experienced a clinically meaningful reduction in MADRS scores.

These results, published in February 2026, suggest that COMP360 “probably meets the bar for approval,” according to Jerry Rosenbaum, director of Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics. While not described as “miraculous,” the data represent a significant step forward in addressing a condition that affects millions worldwide.

Beyond COMP360: The Expanding Psychedelics Market

COMP360 isn’t the only psychedelic therapy gaining traction. Johnson & Johnson’s Spravato, a ketamine derivative, was previously approved for TRD, marking the first psychedelic-based medicine to reach the market. The success of Spravato and the promising results from COMP360 are fueling increased investment and research into other psychedelic compounds, including MDMA for PTSD and potentially others for anxiety and addiction.

The Role of Psychological Support

It’s crucial to note that these therapies aren’t simply about administering a drug. The Compass Pathways approach, and many others in development, emphasize the importance of psychological support alongside the psilocybin treatment. The psychological support model is a “really important aspect of the therapy,” according to experts.

Future Trends in Psychedelic-Assisted Therapy

Several key trends are shaping the future of psychedelic-assisted therapy:

  • Increased Research & Development: Expect to see a surge in clinical trials exploring the efficacy of various psychedelic compounds for a wider range of mental health conditions.
  • Personalized Treatment Approaches: Researchers are investigating how individual factors, such as genetics and brain activity, might influence a patient’s response to psychedelic therapy, leading to more tailored treatment plans.
  • Integration of Digital Health Technologies: Apps and wearable devices could play a role in monitoring patient progress, providing remote support, and enhancing the therapeutic experience.
  • Expanding Access to Care: As these therapies gain approval, efforts will focus on training therapists and establishing clinics to make them accessible to a broader population.
  • Regulatory Landscape Evolution: Governments worldwide are grappling with how to regulate psychedelic therapies, balancing the necessitate for patient safety with the potential benefits of these innovative treatments.

FAQ

What is treatment-resistant depression? TRD is depression that hasn’t responded to at least two different antidepressant treatments.

What is COMP360? COMP360 is Compass Pathways’ synthetic formulation of psilocybin, the psychoactive compound found in magic mushrooms.

Is psilocybin therapy safe? Clinical trials have shown COMP360 to be generally well-tolerated, with no unexpected safety findings. However, it’s important to note that these therapies are typically administered in a controlled clinical setting with trained professionals.

How does psilocybin work in the brain? Research suggests psilocybin affects serotonin receptors in the brain, potentially leading to changes in brain connectivity and improved mood.

When might COMP360 be available? Compass Pathways has requested a meeting with the FDA to discuss a rolling submission for approval, but a timeline for potential market availability is not yet clear.

Did you know? The largest psilocybin treatment clinical trial ever conducted involved 233 patients across 22 sites in 10 countries.

Pro Tip: If you are struggling with depression, talk to your doctor about available treatment options. Psychedelic-assisted therapy may not be right for everyone, but it’s important to be aware of all potential avenues for relief.

Stay informed about the latest developments in mental health and psychedelic therapies. Explore more articles on our website and subscribe to our newsletter for updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Ocular Therapeutix’s Axpaxli Shows Promise in AMD Trial, But Results Mixed

by Chief Editor
written by Chief Editor

Ocular Therapeutix’s Axpaxli: A Potential Shift in Wet AMD Treatment?

The treatment landscape for wet age-related macular degeneration (AMD) may be on the cusp of change. Ocular Therapeutix announced positive results from a late-stage clinical trial of its experimental drug, Axpaxli, demonstrating superior vision maintenance compared to aflibercept (Eylea) in patients with this common cause of blindness. The findings, released on February 17, 2026, signal a potential new option for patients requiring frequent injections.

Axpaxli’s Performance in the SOL-1 Trial

The Phase 3 SOL-1 trial revealed that 74.1% of patients receiving Axpaxli maintained their vision at week 36, a 17.5% risk difference (p=0.0006) compared to those treated with aflibercept. Even at week 52, Axpaxli showed continued benefit, with 65.9% of patients maintaining vision, representing a 21.1% risk difference (p<0.0001) over aflibercept. Notably, 80.6% of patients on Axpaxli were rescue-free at week 24.

A Closer Glance at the Results: Why the Nuance?

Whereas the results are positive, some analysts suggest the margin of superiority wasn’t as large as anticipated. The difference in durability of treatment between Axpaxli and Eylea was “narrower than investors expected,” according to reporting by STAT News. This has sparked debate about Axpaxli’s commercial potential in a market already populated with effective treatments.

The Current Wet AMD Treatment Paradigm

Wet AMD occurs when abnormal blood vessels grow under the retina, leaking fluid and causing vision loss. Current treatments, like Eylea, involve regular injections into the eye to inhibit the growth of these vessels. These injections, while effective, are burdensome for patients and healthcare systems. A treatment offering longer intervals between injections would be a significant advancement.

What Makes Axpaxli Different?

Axpaxli utilizes a different approach to VEGF suppression. The trial data suggests its potency and pan-VEGF suppression capabilities contribute to its superior outcomes. The drug was also generally well-tolerated, with no treatment-related ocular serious adverse events reported in the SOL-1 trial.

Regulatory Pathway and Future Outlook

Ocular Therapeutix plans to submit a New Drug Application (NDA) to the FDA based on the SOL-1 data, following formal discussions with the agency. The detailed trial data will also be presented at the 49th Macula Society Annual Meeting. Approval could position Axpaxli as a competitive alternative to existing therapies, potentially reshaping the treatment algorithm for wet AMD.

The Potential for Reduced Treatment Burden

The promise of fewer injections is a major draw for both patients and physicians. Rescue-free rates with Axpaxli were high, indicating a reduced need for supplemental treatment. If approved, Axpaxli could significantly improve the quality of life for individuals living with wet AMD.

Frequently Asked Questions

Q: What is wet AMD?
A: Wet age-related macular degeneration is an eye disease that causes vision loss due to the growth of abnormal blood vessels under the retina.

Q: How is wet AMD currently treated?
A: Current treatments involve regular injections of drugs that inhibit the growth of these abnormal blood vessels.

Q: What is Axpaxli?
A: Axpaxli is an experimental drug developed by Ocular Therapeutix that aims to provide a more effective and less frequent treatment option for wet AMD.

Q: What were the key findings of the SOL-1 trial?
A: The SOL-1 trial demonstrated that Axpaxli maintained vision in a higher percentage of patients compared to aflibercept, with a reduced need for rescue treatments.

Q: When might Axpaxli be available to patients?
A: Ocular Therapeutix plans to submit an NDA to the FDA, and if approved, Axpaxli could become available to patients in the future.

0 comments
0 FacebookTwitterPinterestEmail
Health

RFK Jr. to Tackle Ultra-Processed Foods Following FDA Petition

by Chief Editor
written by Chief Editor

RFK Jr. Targets Ultra-Processed Foods: A Potential Turning Point for the Food Industry

Health and Human Services Secretary Robert F. Kennedy Jr. Has signaled a significant shift in federal oversight of the food industry, announcing plans to address concerns surrounding ultra-processed foods. This move, revealed on CBS’ “60 Minutes,” centers on a petition submitted by former FDA Commissioner Dr. David Kessler, raising questions about the safety of ingredients commonly found in these products.

The GRAS Controversy and the Kessler Petition

At the heart of the issue is the “Generally Recognized as Safe” (GRAS) designation, a 67-year-old government classification that allows food companies to employ certain ingredients without undergoing a full FDA safety review. Kessler argues this system has enabled the proliferation of ultra-processed foods – those boxed and wrapped in plastic, ready-to-eat items – which now constitute 50% of our calories and 60% of children’s diets.

The petition specifically calls for a reexamination of “processed refined carbohydrates,” including corn syrup, high fructose corn syrup, and refined flours, linking them to health problems like high blood pressure, high triglycerides, and excess abdominal fat. Kessler contends that the current safety status of these ingredients is based on outdated data.

What are Ultra-Processed Foods?

Ultra-processed foods are characterized by ingredients not typically used in home cooking, such as modified starches, hydrogenated oils, and artificial flavors. They are often high in sugar, salt, and unhealthy fats, and are designed to be hyper-palatable – meaning they are engineered to be highly appealing to our taste buds. Examples include sugary drinks, packaged snacks, processed meats, and many ready-to-eat meals.

FDA Response and Potential Next Steps

Kennedy stated, “We will act on David Kessler’s petition,” suggesting a willingness to challenge the status quo. However, the specifics of the FDA’s response remain unclear. The agency is legally required to respond to petitions within 180 days, a deadline that has already passed, but has only issued an “interim response” stating it hasn’t reached a final decision.

The lack of immediate action raises questions about the potential hurdles Kennedy faces in implementing significant changes. The food industry is a powerful lobby, and any attempt to restrict the use of common ingredients is likely to be met with resistance.

A Common Ground on Public Health

This collaboration between Kennedy and Kessler is noteworthy, given their differing views on many other public health issues. Their shared concern over ultra-processed foods highlights a growing consensus that these products pose a significant threat to public health. Kessler has likened the issue to the tobacco crisis, arguing that ultra-processed foods have altered our metabolism and contributed to a dramatic increase in chronic diseases.

The Broader Implications for the Food Industry

Kennedy’s announcement could signal a broader regulatory crackdown on the food industry. Potential outcomes include stricter labeling requirements, limitations on the use of certain ingredients, and increased funding for research into the health effects of ultra-processed foods. This could lead to a shift in consumer behavior, with more people opting for whole, unprocessed foods.

Did you know? The human body has not evolved to efficiently process the high levels of sugar, fat, and artificial ingredients found in many ultra-processed foods.

FAQ

What are ultra-processed foods? These are industrially formulated food products containing ingredients not typically used in home cooking, often high in sugar, salt, and unhealthy fats.

What is the GRAS designation? It stands for “Generally Recognized as Safe” and allows food companies to use certain ingredients without full FDA review.

What is the FDA’s current stance? The FDA has acknowledged Kessler’s petition but has not yet reached a final decision.

Pro Tip: Reading food labels carefully and prioritizing whole, unprocessed foods is the best way to minimize your intake of potentially harmful ingredients.

What does this mean for consumers? This could lead to healthier food options and increased transparency in the food industry.

Stay informed about the evolving landscape of food regulation and its impact on your health. Explore more articles on nutrition and public health to make informed choices about your diet.

0 comments
0 FacebookTwitterPinterestEmail
Health

Dana-Farber Hospital Split: Staff Feel the Strain of Partnership Breakup

by Chief Editor
written by Chief Editor

Boston’s Cancer Care Landscape Shifts: Dana-Farber, Beth Israel, and the Future of Specialized Hospitals

The Boston medical community is experiencing a significant realignment, as Dana-Farber Cancer Institute navigates a latest partnership with Beth Israel Deaconess Medical Center (BIDMC) after ending a decades-long relationship with Brigham and Women’s Hospital. This shift isn’t just a change in affiliations; it signals a potential trend toward more specialized, freestanding cancer hospitals.

A Break from Tradition: Why the Change?

For over 100 years, Brigham and Women’s Hospital had been a key partner in Dana-Farber’s cancer care network. Though, Dana-Farber has chosen to forge a new path with BIDMC, focusing on building a dedicated inpatient cancer hospital. This decision reflects a strategic move to concentrate resources and expertise in a focused environment designed specifically for cancer patients.

The Vision: A Freestanding Cancer Hospital

The collaboration between Dana-Farber and BIDMC centers around the construction of a new, state-of-the-art inpatient cancer hospital in Boston’s Longwood Medical Area. This facility, planned as a 300-bed, 14-story building with a $1.7 billion price tag, aims to be the region’s only independent, freestanding inpatient hospital dedicated to adult cancer patients. Dana-Farber will own the hospital and clinically partner with BIDMC.

Funding the Future: A $1.1 Billion Investment

Beth Israel Lahey Health has filed preliminary bond offerings totaling $1.1 billion to help fund BIDMC’s portion of the new cancer hospital. This substantial financial commitment underscores the seriousness of the project and the anticipated benefits for patients and the medical community.

What Does This Mean for Mass General Brigham?

The departure of Dana-Farber prompted Mass General Brigham (MGB) to establish its own Mass General Brigham Cancer Institute, signaling a renewed focus on cancer care within its existing network. This demonstrates a competitive response to the evolving landscape and a commitment to maintaining a strong presence in oncology.

The Trend Towards Specialization

This move towards specialized cancer hospitals isn’t isolated to Boston. Across the country, there’s a growing recognition of the benefits of concentrating cancer care in dedicated facilities. These benefits include:

  • Enhanced Expertise: Focused teams with specialized knowledge and skills.
  • Advanced Technology: Investment in cutting-edge equipment and therapies tailored to cancer treatment.
  • Improved Patient Experience: A supportive environment designed to meet the unique needs of cancer patients and their families.

Regulatory Hurdles and Timelines

The project has received approvals from state and city regulators, paving the way for construction. However, the transition from the previous partnership with Brigham and Women’s is incremental, with the contract officially ending in 2028. The new cancer hospital is expected to be completed by 2031.

FAQ

Q: What is the main benefit of a freestanding cancer hospital?
A: A dedicated facility allows for a concentration of expertise, technology, and resources specifically focused on cancer care, leading to potentially improved outcomes and patient experience.

Q: Will patients still receive care at Brigham and Women’s Hospital?
A: Yes, Brigham and Women’s Hospital continues to provide advanced cancer care, but It’s no longer directly partnered with Dana-Farber.

Q: When is the new cancer hospital expected to open?
A: The new cancer hospital is anticipated to be completed in 2031.

Q: Who will own the new cancer hospital?
A: Dana-Farber will own the new cancer hospital.

Did you realize? The new hospital is planned to seamlessly connect inpatient, outpatient, and research services, furthering Dana-Farber’s “bench-to-bedside” oncology model.

Explore more about the future of cancer care and the latest advancements in oncology. Read our latest articles or subscribe to our newsletter for updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Advantage Enrollment Growth Slows in 2024 | STAT

by Chief Editor
written by Chief Editor

Medicare Advantage Growth Slows: What’s Behind the Shift?

For years, Medicare Advantage (MA) plans have been the fastest-growing part of Medicare. But new data reveals a significant slowdown. As of February 1, enrollment reached 35.5 million, a modest 3% increase from the previous year. This marks a stark contrast to the 7%-10% annual growth seen between 2017, and 2024.

The Recent Enrollment Dip: A Closer Look

The most recent enrollment window, spanning October 15 to December 7, saw only a 1% increase in MA enrollment. This stagnation raises questions about the future trajectory of the program and the factors influencing seniors’ choices.

Why the Slowdown? Regulatory Scrutiny and Plan Performance

Several factors are likely contributing to this shift. Increased scrutiny from Medicare regulators at the Centers for Medicare and Medicaid Services (CMS) is playing a role. CMS has been “looking into allegations” regarding MA plan practices, signaling a potential tightening of regulations.

Recent reporting by STAT and others has highlighted concerns about how Medicare Advantage plans use algorithms to manage patient care. Investigations have revealed that some plans have improperly denied or limited rehabilitation care for older and disabled patients, prioritizing profits over patient needs. This has led to frustration and anger among patients and healthcare providers alike.

The Impact of Risk Adjustment and Upcoding

The Medicare Advantage program relies on a risk adjustment system to compensate plans for enrolling sicker individuals. Still, there have been concerns about “upcoding,” where plans may inflate the risk scores of their enrollees to receive higher payments from the government. Recent efforts by the federal government to use fresher data aim to rein in this practice.

UnitedHealth Group and the Broader Trend

The slowdown isn’t isolated to a single insurer. Even as specific data on individual plan performance requires a STAT+ subscription, the overall trend suggests a broader cooling of MA’s rapid expansion. UnitedHealth Group, the nation’s largest health insurer, is a key player in the Medicare Advantage market and is likely impacted by these changes.

What Does This Mean for the Future of Medicare Advantage?

The slowing growth of Medicare Advantage doesn’t necessarily signal the program’s decline, but it does indicate a potential turning point. Increased regulatory oversight, coupled with greater awareness of potential issues with plan practices, could lead to a more sustainable – and patient-centered – approach to managed care within Medicare.

FAQ

Q: What is Medicare Advantage?
A: Medicare Advantage plans are offered by private companies approved by Medicare. They provide all Medicare Part A and Part B benefits, and often include extra benefits like vision, dental, and hearing care.

Q: What is upcoding?
A: Upcoding is the practice of inflating the risk scores of patients to receive higher payments from Medicare.

Q: Where can I find more information about Medicare Advantage plans?
A: You can find more information on the Medicare website.

Q: What is STAT+?
A: STAT+ is a subscription service offered by STAT News that provides in-depth analysis of the business of health care.

Did you know? Bob Herman of STAT News has been recognized for his in-depth reporting on the business of health care, particularly his coverage of Medicare Advantage.

Pro Tip: During Medicare open enrollment, carefully compare the costs, benefits, and provider networks of different plans before making a decision.

Want to stay informed about the latest developments in health care? Subscribe to the Health Care Inc. Newsletter for expert analysis and insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

FDA Rejects Disc Medicine’s Porphyria Drug Bitopertin – First Under Makary’s Fast-Track Program

by Chief Editor
written by Chief Editor

FDA Rejection of Disc Medicine’s Bitopertin: A Turning Point for Fast-Tracked Drug Reviews?

The Food and Drug Administration (FDA) on Friday rejected bitopertin, a therapy developed by Disc Medicine for the treatment of porphyria, a rare blood disorder causing extreme sensitivity to sunlight. This decision marks the first rejection under FDA Commissioner Marty Makary’s new program designed to accelerate drug reviews. The rejection sent Disc Medicine shares down 31% to $49 in afternoon trading.

The Commissioner’s Voucher Program: Early Promise and First Setback

Commissioner Makary’s initiative aimed to expedite the review of promising therapies. The program had seen one prior approval – a generic antibiotic in December – raising hopes for a more efficient pathway for innovative drugs. However, the bitopertin case demonstrates that speed doesn’t guarantee approval. The FDA cited “uncertainties” regarding the link between the biomarker used in Disc’s clinical trials and actual clinical benefits for patients.

Biomarkers and Clinical Benefit: A Growing Regulatory Focus

The FDA’s concern highlights a growing trend in regulatory scrutiny: the need for a clear correlation between biomarkers and tangible patient outcomes. Historically, drug approvals have sometimes relied heavily on changes in biomarkers, even without definitive proof of improved health. The agency’s letter suggests a stricter approach, demanding more robust evidence of clinical benefit. This could lead to longer and more expensive clinical trials, particularly for rare disease therapies.

Implications for Rare Disease Drug Development

The rejection of bitopertin could have a chilling effect on investment in rare disease drug development. Companies focusing on rare conditions often face smaller patient populations, making it challenging to conduct large-scale clinical trials. Relying on biomarkers as a surrogate endpoint for clinical benefit is often seen as a pragmatic solution. If the FDA continues to raise the bar for demonstrating clinical benefit, it could significantly increase the risk and cost of bringing these therapies to market.

Adam Feuerstein’s Perspective: A Call for Robust Evidence

Biotech columnist Adam Feuerstein, reporting for STAT News, noted the FDA’s message: “Collect real evidence the drug is effective.” This underscores a broader shift towards data-driven decision-making within the agency. Feuerstein’s coverage suggests the FDA is less willing to accept surrogate endpoints without strong supporting clinical data.

What’s Next for Disc Medicine and the Porphyria Community?

Disc Medicine now faces a critical juncture. The company will need to address the FDA’s concerns and potentially conduct additional clinical trials to demonstrate the clinical benefit of bitopertin. For patients suffering from porphyria, the rejection represents a setback, but it also emphasizes the importance of rigorous scientific evaluation in ensuring the safety and efficacy of new treatments.

FAQ

What is porphyria? Porphyria is a group of rare genetic disorders that result in a buildup of certain chemicals in the body, leading to sensitivity to sunlight and other symptoms.

What is a biomarker? A biomarker is a measurable indicator of a biological state or condition. In clinical trials, biomarkers are often used to assess the effectiveness of a drug.

What is the FDA Commissioner’s voucher program? This program, initiated by Commissioner Marty Makary, aims to fast-track the review of certain drugs.

What does this rejection mean for other drug developers? It suggests the FDA is increasing its scrutiny of the link between biomarkers and clinical benefit, potentially leading to more rigorous requirements for drug approval.

Explore more articles on STAT News to stay up-to-date on the latest developments in the biotech industry.

0 comments
0 FacebookTwitterPinterestEmail
Health

FDA Rejects Moderna’s Flu Vaccine Application After Initial Positive Signals

by Chief Editor
written by Chief Editor

FDA’s Shocking Rejection of Moderna’s Flu Vaccine: A Turning Point for mRNA Technology?

The Food and Drug Administration’s (FDA) decision to refuse review of Moderna’s mRNA-based flu vaccine application has sent shockwaves through the pharmaceutical industry. Moderna President Stephen Hoge described the move as “completely shocking,” raising questions about the future of mRNA vaccine development and the FDA’s evolving standards.

A Billion-Dollar Gamble Rejected

Moderna invested “north of a billion” dollars in the clinical trial, encompassing over 40,000 participants and reaching Phase 3 – the critical stage for regulatory approval. Despite this significant investment and years of collaboration with the FDA, the application was rejected due to concerns over the comparator vaccine used in the trial. The FDA, under Dr. Vinay Prasad, determined the trial didn’t compare the new shot to “the best-available standard of care in the United States at the time of the study.”

The Comparator Controversy

The core of the dispute lies in the benchmark used to evaluate Moderna’s vaccine. The FDA argued the trial should have compared the mRNA vaccine against a high-dose flu vaccine, particularly for older adults, rather than the standard-dose vaccine used. Hoge stated that Moderna had discussed trial designs with regulators for five years, and received confirmation in writing that using a standard-dose influenza vaccine as a comparison was acceptable. The abrupt change in position has left Moderna and industry observers questioning the agency’s consistency.

Implications for the Biopharma Industry

This decision isn’t isolated to Moderna. Hoge warned that the FDA’s actions could “complicate investments in developing new drugs and treatments in the country.” The unexpected rejection raises concerns about regulatory uncertainty and the potential for shifting goalposts, potentially discouraging innovation in the biopharmaceutical sector. The rules of the game, as Hoge put it, “will change after the game is over.”

A Shift in FDA Approach?

Recent statements from Dr. Vinay Prasad suggest a broader re-evaluation of vaccine approval processes. Last fall, Prasad outlined a more rigorous framework for annual flu shots, urging the FDA to rethink its current approach. This suggests the rejection of Moderna’s application may be part of a larger effort to raise the bar for vaccine approvals, focusing on comparisons to the most effective existing treatments.

What Happens Next for Moderna?

Moderna is now left to reassess its strategy and potentially conduct additional trials to meet the FDA’s revised requirements. The company is working to understand the FDA’s concerns and determine the best path forward. The future of its mRNA flu vaccine, and potentially other mRNA-based vaccines, hangs in the balance.

Frequently Asked Questions

What is an mRNA vaccine?

mRNA vaccines use genetic material to teach cells how to make a protein that triggers an immune response, protecting against disease.

What is a ‘comparator’ vaccine?

A comparator vaccine is the existing vaccine used as a benchmark to measure the effectiveness of a new vaccine in clinical trials.

Why did the FDA reject Moderna’s application?

The FDA refused to review the application because it believed the trial compared the new vaccine to an inappropriate benchmark – a standard-dose flu vaccine instead of a high-dose vaccine.

Will this affect other vaccine developers?

Yes, this decision creates uncertainty for other companies developing new vaccines and may lead to more stringent regulatory requirements.

Pro Tip: Staying informed about regulatory changes is crucial for pharmaceutical companies. Regularly monitoring FDA announcements and guidance documents can help avoid unexpected setbacks.

Did you know? Moderna and the FDA collaborated closely for five years on the development of this vaccine, highlighting the complex relationship between pharmaceutical companies and regulatory agencies.

What are your thoughts on the FDA’s decision? Share your opinions in the comments below and explore more articles on vaccine development and regulatory affairs.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts